Institute for Global Health


Sexual Health

Natsal-COVID StudyDr Nigel FieldOngoing
Safetxt: A randomised controlled trial of an intervention delivered by mobile phone messaging to reduce sexually transmitted infections (STI) by increasing sexual health precaution behaviours in young peopleDr John SaundersOngoing
Sixhumene: Using social networks to understand and intervene on HIV epidemic spreadDr Guy HarlingOngoing
British HIV Association (BHIVA) COVID-19 RegistryProf Caroline SabinOngoing
SEQUENCE digital - Sexual health equity through evidence-based online clinical care (Improving sexual health for all, in a digital NHS)Professor Claudia EstcourtOngoing
DISCOVER: A Phase 3, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Emtricitabine and Tenofovir Alafenamide (F/TAF) Fixed-Dose Combination Once Daily for Pre-Exposure Prophylaxis in Men and Transgender Women Who Have Sex with Men and Are At Risk of HIV-1 Infection (GS-US-412-2055)Prof Richard GilsonOngoing
EMERALD: a randomized, active-controlled, open-label study to evaluate the efficacy and safety of switching to a D/C/F/TAF once-daily single-tablet regimen versus continuing the current regimen consisting of a boosted protease inhibitor (bPI) combined with FTC/TDFDr Laura WatersOngoing
T-pal-Omics Study: Syphilis Transcriptomics: Proof of concept study that aims to utilise next generation sequencing and transcriptomic approaches to understand infection with Treponema pallidumDr Patrick FrenchCompleted
Pilot of enhanced LGV surveillance in EuropeDr Nigel FieldCompleted


GS-US-380-1489: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Abacavir/Dolutegravir/Lamivudine in HIV-1 Infected, Antiretroviral Treatment-Naïve AdultsDr Laura WatersOngoing
GS-US-380-1490: A Phase 3, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of GS-9883/Emtricitabine/Tenofovir Alafenamide Versus Dolutegravir + Emtricitabine/Tenofovir Alafenamide in HIV-1 Infected, Antiretroviral Treatment-Naïve AdultsDr Laura WatersOngoing
Royal Free HIV Cohort StudyDr Colette Smith & Dr Fiona LampeOngoing
Siyaphambili YouthDr Andrew GibbsDr Jenevieve MannellOngoing
EuroSIDA: A prospective observational cohort study of HIV-positive individuals in Europe, Israel and ArgentinaProfessor Amanda MocroftOngoing
FLAIR: A Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive ParticipantsProf Sarah PettOngoing
Icona NetworkDr Alessandro Cozzi-LepriOngoing
MAVMET: A multicentre, 48 week randomised controlled factorial trial of adding maraviroc and/or metformin for hepatic steatosis in HIV-1-infected adults on combination antiretroviral therapyProf Sarah PettOngoing
Modelling and cost effectiveness analysis to inform response to high levels of HIV drug resistance in sub-Saharan Africa, including deployment of new drug regimens (HIV Synthesis Model)Professor Andrew PhillipsOngoing
NATSAL: The National Survey of Sexual Attitudes and LifestylesProf Cath Mercer/ Prof Pam SonnenbergOngoing
Needs Informed model of Care for people living with HIV (NICHE)Professor Alison Rodger and Dr Fiona LampeOngoing
POPPY Sleep Substudy: study looking at the effects of being HIV positive and being on antiretroviral medication may have on sleeping and sleep patternProf Caroline Sabin (UCL lead)Ongoing
Positive Voices: The national survey of people living with HIVProf Richard GilsonOngoing
POWER Project: Protecting women from economic shocks to fight HIV in AfricaDr Aurelia LepineOngoing
PrEP IMPACT Trial: A pragmatic health technology assessment of PrEP and implementationProf Richard GilsonOngoing
HIV BioResourceProf Fiona BurnsOngoing
The HIV Modelling ConsortiumProfessor Andrew PhillipsOngoing
AMBER: A Phase 3, randomized, active-controlled, double-blind study to evaluate efficacy and safety of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) once daily fixed dose combination regimen versus a regimen consisting of darunavir/cobicistat fixed dose combination coadministered with emtricitabine/tenofovir disoproxil fumarate fixed dose combination in antiretroviral treatment-naïve human immunodeficiency virus type 1 infected subjects. (TMC114FD2HTX3001)Dr Laura WatersOngoing
Analysing humoral and cellular immune responses to vaccination during chronic infectionDr Dimitra Peppa, Prof Richard Gilson, and Dr Laura WatersOngoing
Assessing the impact of introducing online postal self-sampling for sexually transmitted infections into sexual health provision within the UK on health inequalities, access to care and clinical outcomes (ASSIST)Prof Fiona Burns & Dr Jo GibbsOngoing
Attitudes to, and Understanding of Risk of Acquisition of HIV over time (AURAH2)Prof Alison RodgerOngoing
BESTT Women's Study: Bone Evaluation in HIV-positive women who switch from Truvada/NNRTI to TriumeqDr Laura WatersOngoing
CASCADE studyProfessor Kholoud PorterOngoing
TANGO: A Phase III, randomized, multicenter, parallel-group, non-inferiority study evaluating the efficacy, safety, and tolerability of switching to dolutegravir plus lamivudine in HIV-1-infected adults who are virologically suppressedProf Sarah PettOngoing
TB:HIV - Tuberculosis among HIV-positive Patients: An International Prospective Observational Cohort StudyProfessor Amanda MocroftOngoing
The UK Collaborative HIV Cohort (UK CHIC) StudyProf Caroline SabinOngoing
GS-US-292-1823: A Phase 3b, Randomised, Open-Label Study to Evaluate the Safety and Efficacy of Switching from Regimens Consisting of ABC/3TC plus a Third Antiretroviral Agent to the E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed HIV-1 Infected Adult SubjectsDr Laura WatersCompleted
GS-US-292-1826: A Phase 3b, Randomised, Open-Label Study to Evaluate Switching from a TDF Containing Regimen to E/C/F/TAF Fixed-Dose Combination (FDC) in Virologically-Suppressed, HIV-1 Infected Subjects Aged ≥ 60 YearsDr Laura WatersCompleted
HIV Allocative Efficiency and Financial Commitment Studies in Eastern Europe and Central Asia, using OptimaProf Jolene SkordisCompleted
HIV Indicator Diseases across Europe Study (HIDES)Professor Amanda MocroftCompleted
The Co-morbidities in relation to HIV/AIDS (COBRA) studyProf Caroline SabinCompleted
Data Collection on Adverse events of Anti-HIV Drugs (D:A:D)Prof Caroline Sabin (UCL)/Dr Lene Ryom (CHIP)Completed
EuroCoord: Enhancing clinical & epidemiological HIV research in Europe through cohort collaborationProf Kholoud PorterCompleted
NIHR HPRU: Health Protection Research Unit in Blood Borne and Sexually Transmitted InfectionsProf Caroline SabinCompleted
Optimising the Public Health Benefits of Sex Work Regulation in Senegal: A Formative StudyDr Aurelia LepineCompleted
Partners of people on ART - a New Evaluation of the Risks (The PARTNER study)Prof Alison RodgerCompleted
Positive tRansItions through Menopause (PRIME)Dr Shema TariqCompleted
STAR HIV Self-Testing AfricaDr Valentina Cambiano (UCL lead); Liz Corbett (LSHTM), Karin Hatzold (PSI)Completed
SUPA: Supporting Uptake and adherence to antiretroviralsProf Caroline Sabin (IGH lead)Completed